DOI:

Transcatheter aortic valve implantation for pure severe native aortic regurgitation

Roy D.1, Schaefer U.2, Guetta V.3, Hildick-Smith D.4, Moellman H.5, Dumonteil N.6, Modine T.7, Bosmans J.8, Moat N.9, Linke A.10, Morris C.11, Petronio A.S.12, Champagnac D.13, Medvedofsky D.3, Patterson T.9, Woitek F.8, Jahagiri M.1, Laborde J.C.1, Brecker S.1

Treatment and consequences of regurgitation during transcatheter valve therapies

Transcatheter aortic valve implantation for pure severe native aortic regurgitation

Aims: Transcatheter aortic valve implantation (TAVI) is an established treatment for patients with severe aortic valve stenosis and prohibitive or high surgical risk. There is limited data and experience for TAVI in the treatment of patients with pure severe native valve aortic regurgitation. We aimed to evaluate the off-label treatment of pure native aortic regurgitation (NAR) with TAVI for patients with prohibitive surgical risk by examining the procedural and clinical results from a retrospective worldwide registry of patients with NAR treated with TAVI.

Methods and results: Data on baseline patient characteristics, device and procedural parameters, echocardiographic parameters and outcomes up to June 2012 were collected retrospectively in a uniform spreadsheet from 14 centres that have performed TAVI for pure NAR. A total of 43 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, MN, USA) in 14 centres (mean age 75.3±8.8 years, 53% female, mean logistic EuroSCORE 26.9±17.9%, mean STS score of 10.2±5.3%, n=35 transfemoral, n=4 subclavian, n=3 direct aortic, n=1 carotid). The mean annulus size was 23.7±2.1 mm and the 29 mm prosthesis was most commonly used (n=21 29 mm, n=14 26 mm, n=1 31 mm). Implantation was successful in 42 patients (97.7%) and 8 (18.6%) patients required a second valve during the index procedure for residual aortic regurgitation. In all cases where a second valve was needed, annular calcification was absent (p=0.014). Post-procedure aortic regurgitation ≤ grade I was present in 34 patients (79.1%). All-cause mortality at 30 days was 9.3% (4 patients) and the incidence of major strokes was 4.7% at 30 days. At 12 months, the all-cause mortality was 21.4% (6/28 patients) with a cardiovascular mortality of 10.7% (3 patients).

Conclusions: This represents the first registry analysis of patients being treated with TAVI for the indication of pure severe NAR. TAVI for severe NAR is feasible and can be an effective treatment for patients with prohibitive surgical risk.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved